A test that measures cells’ sulfamidase enzyme activity could help doctors predict the severity of Sanfilippo type A,…
Ana Pena, PhD
Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
Shire, Microsoft and Rare Diseases Europe have formed an alliance to try to accelerate the time it takes to…
BioMarin Presents Phase 1/2 Interim Results for Enzyme Replacement Therapy in Sanfilippo B Syndrome
BioMarin Pharmaceutical announced interim results for its Phase 1/2 trial evaluating BMN 250, an enzyme replacement therapy, for the…